Genocea Biosciences and Eiger Biopharmaceuticals are high risk/high reward plays.
May kicks off with a busy first week filled with earnings, monetary policy and a snapshot of the health of the economy.
Biotech investors should keep a close eye on the progress in this huge potential market.
©1996-2017 TheStreet, Inc. All rights reserved.
Action Alerts PLUS is a registered trademark of TheStreet, Inc.